Moderna (NASDAQ:MRNA) has postponed its plans to set up a vaccine manufacturing plant in Kenya, according to a Financial Times report. The biotech major had entered into a deal with the Kenyan government last year and intended to invest around $200 million in a facility that would produce up to 500 million vaccine shots a year.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Moreover, the Kenyan government gave Moderna several tax breaks and allowed it to more than halve its initial investment of $500 million.
Moderna confirmed to the Financial Times that it had paused the construction of a vaccine plant in Kenya. This decision was prompted by decreasing sales of its COVID-19 vaccine in Africa after the pandemic. As a result, it did not consider the investment in a plant in Kenya as “viable.”
The report cited analysts’ estimates, projecting MRNA to generate total COVID-19 vaccine sales of $3.9 billion this year. This marks a steep decline of 79% from its peak vaccine sales of $18.4 billion in 2022.
What Is the Forecast for MRNA Stock?
Analysts remain cautiously optimistic about MRNA stock, with a Moderate Buy consensus rating based on nine Buys, six Holds, and two Sells. Over the past year, MRNA has declined by more than 30%, and the average MRNA price target of $134.56 implies an upside potential of 28.6% from current levels.
